ONE WORLD CANNABIS Israeli-based Leading Edge Cannabis Research OWC Pharmaceutical Research Corp. (OTCQB:OWCP) is engaged in the business, through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development of cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, PTSD, migraines, and of a unique delivery system. One World Cannabis Ltd., is focused on discovering, developing and commercializing cannabis-based novel therapeutics products and treatments specifically designed for several medical conditions, starting with multiple myeloma, psoriasis, fibromyalgia, PTSD (post-traumatic stress disorder) and migraines. One World Cannabis is a young company that, despite its youth, is already playing a part in making history. CANNAINVESTOR Magazine The expert team delivers years of proven practices in diverse disciplines, including medical science and regulatory affairs, as well as extensive cannabis-related issues experience. One World Cannabis aspires to become one of the world’s leading players in the hyper-growing market of medical cannabis by providing the missing yet prerequisite element of scientific validity for cannabis based products. The Company is committed to and the highest standards of integrity and ethics in proposing, conducting and reporting research. All its investigations and researches are conducted at the facilities of leading Israeli medical centers, as well as at the labs of the R&D pharmaceutical companies we contracted with. The Company adheres to all the necessary regulatory requirements, including submitting its research protocols to Ethics Committee (IRB) approval.